Investors should monitor upcoming Q2 2026 data readouts from Cohort C and the initiation of the pivotal trial for TSC-101, which could serve as major value inflection points. The expanded pipeline with FDA-cleared INDs increases long-term optionality. Reduced cash burn extends runway without near-term dilution risk.
TCRX drugs
TCRX drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK AT ENTRY AT T+60- T+0 · Mar 4 $1.08entry
- T+1 · 9mo ago +4.63%α +5.20% · $1.13
- T+5 · 8mo ago +6.48%α +7.81% · $1.15
- T+20 · 8mo ago −4.63%α −0.21% · $1.03
- T+60 · 6mo ago 0.00%α −10.09% · $1.08
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
TScan Therapeutics reported financial results for Q4 and full-year 2025, highlighted by a 268% year-over-year increase in revenue to $10.3M driven by its Amgen collaboration, while R&D and G&A expenses declined QoQ. The company presented positive Phase 1 ALLOHA™ trial data showing improved survival trends and completed enrollment in Cohort C using its commercial-ready manufacturing process. FDA clearance of two new TCR-T candidates (TSC-102-A01/A03) expands its heme malignancy pipeline. Cash remains strong at $152.4M, sufficient to fund operations into H2 2027.
Key Financial Metrics
Key Facts
- Q4 2025 revenue: $2.6M (vs. $0.7M in Q4 2024), full-year 2025 revenue: $10.3M (vs. $2.8M in 2024), driven by Amgen collaboration
- Q4 2025 R&D expenses down 32% YoY to $20.0M; full-year R&D up slightly to $114.2M
- Net loss narrowed to $23.0M in Q4 2025 (vs. $35.8M in Q4 2024)
- Positive ALLOHA™ Phase 1 data: 100% (3/3) of TSC-101-treated patients relapse-free at 2-year follow-up vs. 25% (1/4) in control
- FDA cleared INDs for TSC-102-A01 and TSC-102-A03 targeting CD45 in HLA-A*01:01 and A*03:01 patients
- Cohort C enrollment completed with commercial-ready manufacturing; data expected Q2 2026
- Cash and cash equivalents: $152.4M as of Dec 31, 2025, funding operations into H2 2027
- Pivotal trial for TSC-101 to launch in Q2 2026
Financial Impact
Revenue increased by $7.5M YoY; net loss improved by $2.3M annually despite higher R&D spend; cash burn reduced significantly in Q4
Risk Factors
- Clinical development risk: Early-phase data may not translate into pivotal trial success
- High share count dilution: Pro forma shares exceed 129.9M due to pre-funded warrants
- Reliance on Amgen collaboration for revenue; future payments dependent on milestones
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3249222 |
Track record
15 reports on TCRX
5 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +77.60% at T+60 after the Aug 18, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Bearish 7/10 Entry $0.1680 Now $0.1450 +13.69% settles Nov 19
- Oct 26, 202621d ago DEF 14A Bearish 6/10 Entry $0.1897 to $0.1745 Now $0.1450 +23.56% ▲ +8.01% +6.75% vs SPY
- Oct 16, 20264w ago 8-K Neutral 2/10 Entry $0.2102 to $0.1897 Now $0.1450 −31.02% ▼ −9.75% −9.61% vs SPY
- Sep 30, 20266w ago 8-K Neutral 2/10 Entry $0.3175 to $0.2282 Now $0.1450 −54.33% ▼ −28.13% −29.43% vs SPY
- Sep 25, 20267w ago SC 13G Neutral 3/10 Entry $0.3400 to $0.2953 Now $0.1450 −57.35% ▼ −13.15% −14.35% vs SPY
- Sep 11, 20269w ago 8-K Neutral 5/10 Entry $0.3204 to $0.3119 Now $0.1450 −54.74% ▼ −2.65% −2.43% vs SPY
- Sep 2, 202610w ago 8-K Bearish 7/10 Entry $0.3810 to $0.3179 Now $0.1450 +61.94% ▲ +16.56% +15.60% vs SPY
- Aug 18, 202612w ago 8-K Bearish 7/10 Entry $0.7500 to $0.7774 Now $0.1450 +80.67% ▼ −3.65% −4.04% vs SPY
- Aug 12, 202613w ago 8-K Bearish 6/10 No price data
- Aug 12, 202613w ago Press Release Bearish 6/10 Entry $0.7730 to $0.7500 Now $0.1450 +81.24% ▲ +2.98% +2.53% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers